Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

Sumit Madan, Martha Q. Lacy, Angela Dispenzieri, Morie A. Gertz, Francis Buadi, Suzanne R. Hayman, Kristen Detweiler-Short, David Dingli, Steven Zeldenrust, John Lust, Philip R. Greipp, S. Vincent Rajkumar, Shaji Kumar

Blood (2011) 118 (7): 1763–1765.

https://doi.org/10.1182/blood-2011-04-350009

Published: 2011

Journal Articles

Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma

Sumit Madan, MD, Martha Lacy, MD, Angela Dispenzieri, MD, Morie Gertz, MD, Francis Buadi, MD, Suzanne R. Hayman, MD, Kristen Detweiler-Short, David Dingli, M.D., Ph.D., Steven Zeldenrust, MD, John Lust, MD, PhD, Philip R. Greipp, MD, S. Vincent Rajkumar, MD, Shaji Kumar, MD

Blood (2010) 116 (21): 1964.

https://doi.org/10.1182/blood.V116.21.1964.1964

Published: 2010

Journal Articles

Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score

Shaji Kumar, MD, Morie Gertz, MD, Martha Lacy, MD, David Dingli, MD, PhD, Suzanne R. Hayman, MD, Francis Buadi, MD, Kristen Detweiler-Short, Steven Zeldenrust, MD, Nelson Leung, MD, Philip R. Greipp, MD, John Lust, MD, PhD, Stephen Russell, MD, PhD, Robert Kyle, MD, Vincent Rajkumar, Angela Dispenzieri, MD

Blood (2010) 116 (21): 1892.

https://doi.org/10.1182/blood.V116.21.1892.1892

Published: 2010

Journal Articles

Multi-Parameter Flow Cytometry(FC) Can Detect Proliferating Myeloma Cells After Treatment: Implications for Targeting the Myeloma Proliferative Component

John Lust, MD, PhD, Shaji Kumar, MD, Michael Timm, Kathleen Donovan, PhD, Philip R. Greipp, MD, William Morice, MD, PhD

Blood (2010) 116 (21): 4995.

https://doi.org/10.1182/blood.V116.21.4995.4995

Published: 2010

Journal Articles

Reduction In Proliferative Rate of Myeloma Plasma Cells Measured by the Plasma Cell Labeling Index Predicts Improved Survival In Multiple Myeloma

Jeremy T Larsen, MD, Cheng E. Chee, MD, John Lust, MD, PhD, Philip R. Greipp, MD, S. Vincent Rajkumar, MD

Blood (2010) 116 (21): 4048.

https://doi.org/10.1182/blood.V116.21.4048.4048

Published: 2010

Journal Articles

Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease

Blood (2010) 116 (21): 863.

https://doi.org/10.1182/blood.V116.21.863.863

Published: 2010

Journal Articles

Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function

Shaji Kumar, MD, Angela Dispenzieri, M.D., Martha Lacy, MD, Suzanne R. Hayman, MD, Francis Buadi, MD, David Dingli, M.D., Ph.D., Kristen Detweiler-Short, RN, John Lust, Steven Zeldenrust, MD, Stephen Russell, MD, PhD, Philip R. Greipp, MD, Robert Kyle, MD, Morie Gertz, MD, Vincent Rajkumar

Blood (2010) 116 (21): 2970.

https://doi.org/10.1182/blood.V116.21.2970.2970

Published: 2010

Journal Articles

Phase II Trial of Lenalidomide (Revlimid ™ ) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma

Blood (2008) 112 (11): 91.

https://doi.org/10.1182/blood.V112.11.91.91

Published: 2008

Journal Articles

14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).

Alan H. Bryce, MD, Rhett Ketterling, MD, Morie Gertz, MD, Steve Zeldenrust, MD, Martha Lacy, MD, Shaji Kumar, MD, Suzanne Hayman, MD, Francis Buadi, MD, Phillip Greipp, MD, John Lust, MD, Vincent Rajkumar, MD, Rafael Fonseca, MD, David Dingli, MD, Stephen Russell, MD, Robert Kyle, MD, Angela Dispenzieri, MD

Blood (2007) 110 (11): 2477.

https://doi.org/10.1182/blood.V110.11.2477.2477

Published: 2007

Journal Articles

Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.

Suzanne Hayman, MD, Morie Gertz, MD, Martha Lacy, MD, Angela Dispenzieri, MD, Rafael Fonseca, MD, Susan Geyer, PhD, Shaji Kumar, MD, Steven Zeldenrust, MD, Stephen Russell, MD, PhD, John Lust, MD, PhD, Robert Kyle, MD, Philip Greipp, MD, Thomas Witzig, MD, S. Vincent Rajkumar, MD

Blood (2006) 108 (11): 3568.

https://doi.org/10.1182/blood.V108.11.3568.3568

Published: 2006

Journal Articles

Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Reduced Renal Function: A Matched Set Comparison.

Shaji Kumar, MD, Martha Lacy, MD, Angela Dispenzieri, MD, Suzanne Hayman, MD, Nelson Leung, MD, Vincent Rajkumar, MD, Steven Zeldenrust, MD, John Lust, MD, Philip Greipp, MD, Dennis Gastineau, MD, Morie Gertz, MD

Blood (2006) 108 (11): 3091.

https://doi.org/10.1182/blood.V108.11.3091.3091

Published: 2006

Journal Articles

Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.

Martha Lacy, MD, Morie Gertz, MD, Angela Dispenzieri, MD, Suzanne Hayman, MD, Susan Geyer, PhD, Steven Zeldenrust, MD, Shaji Kumar, MD, Philip Greipp, MD, Rafael Fonseca, MD, John Lust, MD, Stephen Russell, MD, PhD, Robert Kyle, MD, Thomas Witzig, MD, Leif Bergsagel, MD, S. Vincent Rajkumar, MD

Blood (2006) 108 (11): 798.

https://doi.org/10.1182/blood.V108.11.798.798

Published: 2006

NARROW

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma

Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score

Multi-Parameter Flow Cytometry(FC) Can Detect Proliferating Myeloma Cells After Treatment: Implications for Targeting the Myeloma Proliferative Component

Reduction In Proliferative Rate of Myeloma Plasma Cells Measured by the Plasma Cell Labeling Index Predicts Improved Survival In Multiple Myeloma

Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease

Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function

Phase II Trial of Lenalidomide (Revlimid ™ ) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma

14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).

Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.

Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Reduced Renal Function: A Matched Set Comparison.

Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only